EGFR and hepatocellular carcinoma: In a recent study published in Nature, Jin et al.1 adopted CRISPR screening to dissect the resistance of hepatocellular carcinoma to lenvatinib, discovering the synergistic effect of EGFR inhibitor (gefitinib) and lenvatinib (multi-tyrosine kinase inhibitor, muti-TKI) combination therapy with encouraging clinical benefits.